Home Sectors Healthcare Valuation Now: Masimo Corporation (NASDAQ: MASI)

Valuation Now: Masimo Corporation (NASDAQ: MASI)

SHARE

Masimo Corporation is part of the medical instruments and equipment industry and is part of the healthcare sector. The company CEO is Joseph E. Kiani. Masimo Corp is a medical technology company. The company develops, manufactures, and markets noninvasive monitoring technologies. Its product includes noninvasive blood constituent and brain and breath monitoring.

Previous Intraday Trading Performance:

The MASI stock showed a previous change of 2.59% with an open at 130.71 and a close of 132.50. It reached an intraday high of 132.64 and a low of 129.98.

Business Wire:  NuVision Management Healthcare Consulting Company, One of the Largest U.S. Providers of Long-term Care for Medically Complex Children, Converts to Masimo

Liquidity:

The stock has a market cap of $7.1b with 53.4m shares outstanding, of which the float is 51.7m shares. Trading volume reached 465,853 shares compared to its average volume of 486,424 shares. Based on the current average volume and close price, the trading liquidity is good.

Historical Trading Performance:

Over the last five trading days, Masimo Corporation shares returned -3.38% and in the past 30 trading days it returned 4.26%. Over three months, it changed -0.88%. In one year it has changed 32.86% and within that year its 52-week high was 147.91 and its 52-week low was 96.14. MASI stock is 37.82% above its 52 Week Low.

Our calculations show a 200 day moving average of 122.41 and a 50 day moving average of 135.04. Currently MASI stock is trading 8.24% above its 200 day moving average.

Business Wire:  NuVision Management Healthcare Consulting Company, One of the Largest U.S. Providers of Long-term Care for Medically Complex Children, Converts to Masimo

Earnings:

The last annual fiscal EPS for the company was reported at 3.49 that ended on 31st of December 2018, which according to the previous close, that is a PE of 37.97. Based on 4 analyst estimates, the consensus EPS for the next quarter is 0.75. The TTM EPS is 3.02, which comes to a TTM PE of 43.87. Historically, the PE high was 56.90 and the PE low was 11.80. If the stock reached its PE low, that would represent a price of 35.64, which is a decrease of -73.10%.

Below was the last reported quarterly diluted earnings per share:

1stQtr of 2019 (Reported on 05/06/2019): 0.87
4thQtr of 2018 (Reported on 02/26/2019): 0.83
3rdQtr of 2018 (Reported on 10/31/2018): 1.02
2ndQtr of 2018 (Reported on 08/01/2018): 0.79
1stQtr of 2018 (Reported on 05/02/2018): 0.82

Base on our calculations, the intrinsic value per share is 91.98, which means it may be overvalued by -44.05%.

Indicators to Watch:

The current calculated beta is 1.11.

SeekingAlpha:  Sector Study: Consumer Cyclical Vs. Consumer Defensive Dividend Dogs, Which To Buy?

Fundamental Indicators:

Based on last reported financials, the company’s return on equity is 22.27%, return on assets is 18.53%, profit margin is 22.49%, price-to-sales is 7.86 and price-to-book is 6.86.

Company Scores:

All scores are out of six:
 1  :Valuation Score
 4  :Past Performance Score
 5  :Financial Strength Score
 2  :Future Growth Score
 0  :Dividend Score
 3  :Overall Score

SHARE
John Jones
Worked for several Wall Street firms: Salomon Smith Barney, UBS, and Charles Schwab. Has developed skills and gained extensive experience over the years that is used today to uncover winning penny stocks.Also was an attorney for small businesses in Scottsdale, Arizona. That experience and understanding of law provides a unique perspective and edge in discovering quality companies in various industries.